Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy and Zoledronic Acid for Bone Metastasis in GI Cancer
NCT02784652Phase 2Completed
- Sponsor
- Severance Hospital
- Start
- Jun 2014
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zoledronic acid in bone metastasis, sponsored by Severance Hospital. Primary endpoint: Pain relief rate at 6 months. Started Jun 2014; status: completed.
02
Drugs
zoledronic acid
03
Conditions
bone metastasis
Beyond the preview
Go deeper on NCT02784652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02784652.